+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Doxorubicin - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 288 Pages
  • July 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5302837

Global Doxorubicin Market to Reach $1.3 Billion by 2026


Doxorubicin, a medical compound originally derived from Streptomyces peucetius bacterium, received approval for clinical use in the USA in 1974. Doxorubicin is available in different forms including pegylated and in liposomes versions. In medical settings, Doxorubicin (Dox) is commonly used for treating cancers of breast, bladder, stomach, ovaries, lung, soft tissue sarcoma, thyroid, multiple myeloma, Hodgkin`s lymphoma, and leukemias, among others. Doxorubicin is a key drug in the treatment of breast malignancy, Kaposi Sarcoma and several other diseases. Growth in the global market is set to be driven by rising incidence of cancer, development of technologically advanced systems for drug delivery, increasing awareness levels among patients and rising disposable incomes of people. Doxorubicin use is anticipated to increase significantly for ovarian cancer treatment and treatment of AIDS-related Kaposi`s sarcoma following failure of systemic chemotherapy done previously. Increasing number of hepatocellular carcinoma and growing survival rates also constitutes a major growth driver.

Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$1.3 Billion by 2026, growing at a CAGR of 5.3% over the analysis period. Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$313.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lung Cancer segment is readjusted to a revised 6.9% CAGR for the next 7-year period. This segment currently accounts for a 16.5% share of the global Doxorubicin market. Breast cancer represents a major category due to the constantly rising prevalence of breast cancer. Myocet, a non-pegylated liposomal doxorubicin, is approved in Canada and the European Union to treat metastatic breast cancer in combination with cyclophosphamide. Increasing incidence of lung cancer and rising awareness about available therapies is fueling demand for doxorubicin.

The U.S. Market is Estimated at $443.5 Million in 2022, While China is Forecast to Reach $106.6 Million by 2026


The Doxorubicin market in the U.S. is estimated at US$443.5 Million in the year 2022. The country currently accounts for a 40.56% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$106.6 Million in the year 2026 trailing a CAGR of 7.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$113.8 Million by the end of the analysis period. The US represents the largest regional market owing to the presence of a high number of people with different malignant tumors including lung, prostate, bladder, colon, breast and other malignancies. Use of the drug is high in the region, in mono as well as combination chemotherapies. The well-developed healthcare infrastructure facilities in the country and high adoption of technologically advanced treatment methods for cancer are positioning the US as a major market for cancer therapies. Asia-Pacific represents another key market, due to rising cancer prevalence in the region, increasing awareness about various cancer therapies, and growing collaborations between private and public sectors to offer new cancer therapies in the region.

Ovarian Cancer Segment to Reach $179.7 Million by 2026


Liposomal delivery systems have considerably improved the safety and efficacy of chemotherapeutic agents, in comparison to non-liposomal formulations. The increasing prevalence of ovarian cancer spurs growing use of various forms of liposomal doxorubicin such as Caelyx/Doxil. In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$122.9 Million will reach a projected size of US$155.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.8 Million by the year 2026, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 59 Featured):

  • Accord Healthcare Ireland Ltd
  • Cadila Healthcare Limited
  • Changzhou Kinyond Pharmaceutical Co., Ltd
  • Cipla, Limited
  • Hikma Thymoorgan Pharmazie GmbH
  • Janssen-Cilag Pty Limited
  • Meiji Seika Pharma Co., Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Novartis International AG
  • Pfizer, Inc.
  • Reddy's Laboratories Ltd.
  • Synbias Pharma AG
  • Teva Pharmaceutical Industries Ltd
  • TTY Biopharm Company Limited

What`s New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to the digital archives
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Doxorubicin - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Cancer - An Insight
  • Cancer Treatment
  • Chemotherapy: An Overview
  • An Introduction to Doxorubicin
  • Impact of Covid-19 and a Looming Global Recession
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • COVID-19 Impact on Global Doxorubicin Market
  • GLOBAL MARKET OVERVIEW
  • Global Doxorubicin Market Set to Witness Rapid Growth
  • US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
  • Breast Cancer Constitutes the Largest Application for Doxorubicin
  • Competition
  • New Entrants Seek Opportunities
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rise in Cancer Incidence to Drive Market Growth
  • Breakdown of Total Number of Cancer Cases by Region: 2020
  • Breakdown of Total Number of Cancer Cases by Type: 2020
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Liposomal Delivery Systems Offer Significant Benefits
  • A Review of Liposomal-Doxorubicin Preparations
  • DOX Hydrochloride
  • Ageing Demographics to Drive Demand
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Market to Gain from Rise in Number of Breast Cancer Cases
  • Select Doxorubicin Phase IV and Phase III Completed Clinical Trials for Breast Cancer with Results: As of Dec 30, 2019
  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
  • Uptrend in Healthcare Spending Drives the Doxorubicin Demand
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • Cancer Research Spending Continues to Witness Growth
  • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • A Netherland’s Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect (2020) (The Netherlands)
  • Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
  • Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
  • Combination Therapy: A Double Whammy Success
4. GLOBAL MARKET PERSPECTIVEIII. MARKET ANALYSIS
UNITED STATES
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • MARKET ANALYSIS
  • Rising Cancer Cases Spur Growth in Doxorubicin Market
  • Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
  • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
CANADA
  • Number of New Cancer Cases in Canada: 2019
JAPAN
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
CHINA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
EUROPE
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • MARKET ANALYSIS
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
FRANCE
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
GERMANY
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
ITALY
UNITED KINGDOM
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • MARKET ANALYSIS
  • An Insight into Asia-Pacific Market for Doxorubicin
  • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
AUSTRALIA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
INDIA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
IV. COMPETITION
  • Total Companies Profiled: 59

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Accord Healthcare Ireland Ltd
  • Cadila Healthcare Limited
  • Changzhou Kinyond Pharmaceutical Co., Ltd
  • Cipla, Limited
  • Hikma Thymoorgan Pharmazie GmbH
  • Janssen-Cilag Pty Limited
  • Meiji Seika Pharma Co., Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Novartis International AG
  • Pfizer, Inc.
  • Reddy's Laboratories Ltd.
  • Synbias Pharma AG
  • Teva Pharmaceutical Industries Ltd
  • TTY Biopharm Company Limited